ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO1074

Efficacy and Safety of Short-Term Treatment with Sodium Zirconium Cyclosilicate (ZS-9) for Hyperkalemia: Open-Label, Phase 3 Trial

Session Information

Category: Fluid, Electrolytes, and Acid-Base

  • 704 Fluid, Electrolyte, Acid-Base Disorders


  • Packham, David K., U. of Melbourne, Melbourne, New South Wales, Australia
  • Fishbane, Steven, Hofstra Northwell Health School of Med., Great Neck, New York, United States
  • Pergola, Pablo E., Renal Associates PA, San Antonio, Texas, United States
  • Lerma, Edgar V., UIC/ Advocate Christ, Oak Lawn, Illinois, United States
  • Butler, Javed, Stony Brook U., Stony Brook, New York, United States
  • Von haehling, Stephan, U. of Göttingen Medical Centre, Göttingen, Germany
  • Adler, Scott H., AstraZeneca, Gaithersburg, Maryland, United States
  • Singh, Bhupinder, ZS Pharma Inc., part of AstraZeneca, San Mateo, California, United States
  • Lavin, Philip T., Boston Biostatistics Research Foundation, Framingham, Massachusetts, United States
  • McCullough, Peter A., Baylor U. Medical Center, Dallas, Texas, United States
  • Kosiborod, Mikhail, Saint Luke’s Mid America Heart Institute, Kansas City, Missouri, United States
  • Spinowitz, Bruce S., New York Presbyterian Queens, New York, New York, United States

Correction of hyperkalemia (HK) is important for the clinical management of patients (pts). Sodium zirconium cyclosilicate (ZS-9) is a selective, inorganic, potassium (K)-binder. We report results of ≤72h of ZS-9 treatment from the largest study of treated HK pts to date.


This international, open-label, single-arm trial with no dietary K or RAASi restrictions enrolled 751 outpatients (≥18y) with HK (K≥5.1mmol/L). Pts received 10g ZS-9 TID for 24–72h until normokalemic (K3.5–5.0 mmol/L; blood K measured by point-of-care device [iSTAT]). Treatment decisions were based on iSTAT K, generally considered to be highly accurate; efficacy endpoints were based on serum K from central lab per usual practice. Endpoints were achievement of normokalemia, overall response rate (%), change in K from baseline (ΔK), and adverse events (AE).


99.3% of pts completed. By 24h, ΔK was -0.8 mmol/L (iSTAT, -14.9%; from 5.5 to 4.7 mmol/L) and -0.7 mmol/L (serum, -12.7%; from 5.6 to 4.9 mmol/L). Overall, 99.5% (95% CI [99%, 100%]) of pts achieved normokalemia by iSTAT and 77.9% (95% CI [75%, 81%]) by serum K. 100% of pts experienced a reduction in K (regardless of measurement method) with 92% having K reductions ≥0.5 mmol/L; 0.4% of pts had iSTAT K>5.0mmol/L and 22% had serum K>5.0mmol/L (Figure). 4.1% of pts experienced an AE. Most common were nausea (0.5%) and urinary tract infection (UTI; 0.5%); 1 pt each had peripheral edema and serum K3.0-<3.5mmol/L. UTI was the 1 SAE (resulting in the only hospitalization), and 2 pts discontinued due to AEs (UTI, flatulence, and upper abdominal pain). No deaths occurred.


ZS-9 rapidly and reliably normalized K in nearly all HK pts, with a safety profile similar to prior studies.


  • Commercial Support